The openFDA Drugs@FDA record for NDA 022231 shows a newly approved supplement on Mallinckrodt's TERLIVAZ — terlipressin acetate, supplied as a powder for intravenous use at a strength equivalent to 0.85 mg of base per vial. The submission, SUPPL-4, is classified LABELING and carries a status of AP (approved) on a standard review track. On its face it is a prescribing-information update. Read against the application's full history, it is the latest line on the record of a drug that took an unusually long and contested path to becoming the first of its kind.
That history is in the same record. TERLIVAZ's original submission (ORIG-1) was approved on 14 September 2022, classified Type 1 — New Molecular Entity and — critically — granted priority review. Priority review is the FDA's signal that a drug, if effective, would be a significant improvement in the treatment of a serious condition. The serious condition here is hepatorenal syndrome (HRS), and the 'significant improvement' was that, before TERLIVAZ, the United States had no FDA-approved therapy for it.
What hepatorenal syndrome is, and why a drug for it mattered
Hepatorenal syndrome is acute kidney failure that develops in patients with advanced liver disease — typically cirrhosis with ascites. The kidneys are structurally intact, but the circulatory derangements of end-stage liver disease collapse renal blood flow, and kidney function falls fast. The fast-declining form is a medical emergency with a grim short-term prognosis; for many patients the only definitive fix is a liver transplant they may not survive long enough to receive. Terlipressin is a vasoconstrictor that works by constricting the splanchnic vasculature, redirecting blood flow and supporting renal perfusion. It had been used outside the United States for years, but it lacked an FDA approval, leaving American clinicians to manage HRS off-label and improvise.
TERLIVAZ closed that gap. As the first FDA-approved product indicated for HRS with rapid reduction in kidney function, it converted an unmet need into an approved, labeled, reimbursable hospital therapy. The priority-review designation in the Drugs@FDA record is the regulatory fingerprint of that significance. The road there was not smooth — terlipressin's U.S. development history included regulatory setbacks before the 2022 clearance — which makes the eventual first-in-class approval the more notable as a commercial and clinical milestone.
Reading a labeling supplement on a first-in-class drug
So what does SUPPL-4 do? The openFDA record tells us its class — labeling — and its status — approved — but not the verbatim text of what changed. A labeling supplement updates the prescribing information: it can refine dosing guidance, add or sharpen safety language, incorporate post-marketing data, or adjust the description of the patient population. For a narrow-indication, hospital-administered drug with a meaningful safety profile, an evolving label is normal and expected; it reflects accumulating real-world experience being folded back into the official document clinicians rely on. The record shows TERLIVAZ already took one labeling supplement (SUPPL-1, approved January 2023) before this one, so the application has a pattern of label maintenance.
The business frame theradeals applies is about value, not just clinical detail. A first-in-class drug for a serious condition with no prior approved option occupies a defensible commercial position: it is the standard against which any future entrant is measured, and the label is part of that moat. Each approved labeling supplement keeps the drug's official profile current and competitive. For a sponsor, an up-to-date, FDA-blessed label is an asset — it governs how the drug can be marketed and prescribed, and a stale label can become a liability as the evidence base moves.
Why the corporate context matters
The record lists the application holder as Mallinckrodt, and the corporate backdrop is part of the story for any reader treating this as an asset. Mallinckrodt has navigated significant financial and restructuring turbulence in recent years. In that context, a product like TERLIVAZ — first-in-class, priority-reviewed, addressing a condition with no prior approved therapy — is exactly the kind of differentiated asset a company under pressure wants to keep healthy and well-tended. A labeling supplement is one of the routine, low-drama ways a sponsor demonstrates it is actively maintaining a product rather than letting it stagnate.
The discipline here is the same one applied to any regulatory record: read the class of the event before assigning it weight. SUPPL-4 is a labeling supplement, not a new indication or a new molecular entity, so the addressable market did not change on this approval. What the filing confirms is that the first-in-class HRS therapy remains an actively managed application, its label kept current four years after the molecule cleared. The deeper signal is in the arc the openFDA record traces: a priority-reviewed 2022 first-in-class approval, followed by steady label maintenance through 2026. That is what a defended, narrow-population franchise looks like in the public regulatory data — and the Drugs@FDA record is where it is written down.
Why first-in-class is a fragile kind of moat
The commercial paradox of a drug like TERLIVAZ is worth spelling out for readers who treat therapeutics as an asset class. Being first-in-class for a serious condition with no prior approved option is genuinely valuable — it confers pricing power, clinical-guideline incumbency, and the status of the reference therapy. But it is also a fragile moat in some respects. The indication, hepatorenal syndrome with rapid kidney-function decline, is narrow and hospital-bound; the patient population is severely ill; and the drug carries a meaningful safety profile that demands careful use. Those constraints cap the addressable market even as they make the approval medically important. The value of the asset therefore depends heavily on careful stewardship — keeping the label current, supporting appropriate use, and defending the first-mover position before any future competitor or generic erodes it.
That stewardship is exactly what a string of approved supplements represents. SUPPL-1 in 2023 and SUPPL-4 now are the visible evidence that the sponsor is keeping the dossier alive rather than letting a hard-won, narrow-indication asset stagnate. For a company managing through financial pressure, that ongoing investment in a differentiated product is a rational choice: first-in-class assets are scarce, and a current label is the difference between a marketable franchise and a parked approval. The openFDA record does not editorialize, but the cadence it shows speaks clearly enough.